Equities research analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings of ($0.78) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Ascendis Pharma A/S’s earnings. The highest EPS estimate is ($0.69) and the lowest is ($0.82). Ascendis Pharma A/S reported earnings per share of ($0.60) in the same quarter last year, which suggests a negative year-over-year growth rate of 30%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, August 30th.

On average, analysts expect that Ascendis Pharma A/S will report full year earnings of ($3.15) per share for the current year, with EPS estimates ranging from ($3.32) to ($2.90). For the next year, analysts expect that the business will report earnings of ($2.82) per share, with EPS estimates ranging from ($3.39) to ($2.33). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, May 23rd. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.19. Ascendis Pharma A/S had a negative net margin of 1,944.88% and a negative return on equity of 58.53%. The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $1.10 million.

Several research analysts have recently commented on the company. Leerink Swann lowered Ascendis Pharma A/S from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $24.00 to $30.00 in a report on Thursday, March 9th. Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, March 24th. Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. J P Morgan Chase & Co assumed coverage on shares of Ascendis Pharma A/S in a report on Thursday, May 11th. They issued an “overweight” rating and a $36.00 price objective on the stock. Finally, ValuEngine upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday, May 27th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Ascendis Pharma A/S has an average rating of “Hold” and an average target price of $29.60.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/12/ascendis-pharma-as-asnd-expected-to-post-earnings-of-0-78-per-share.html.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded down 5.89% during midday trading on Monday, hitting $22.54. 403,614 shares of the stock traded hands. The stock’s market cap is $732.60 million. The company’s 50 day moving average price is $26.55 and its 200-day moving average price is $24.95. Ascendis Pharma A/S has a 12-month low of $12.25 and a 12-month high of $31.86.

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in shares of Ascendis Pharma A/S by 23.6% in the first quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 1,020 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Ascendis Pharma A/S during the first quarter valued at about $144,000. Karp Capital Management Corp bought a new stake in shares of Ascendis Pharma A/S during the first quarter valued at about $203,000. Morgan Stanley raised its stake in shares of Ascendis Pharma A/S by 1,446.2% in the first quarter. Morgan Stanley now owns 10,236 shares of the biotechnology company’s stock valued at $287,000 after buying an additional 9,574 shares during the period. Finally, Geode Capital Management LLC bought a new stake in shares of Ascendis Pharma A/S during the first quarter valued at about $414,000. Hedge funds and other institutional investors own 65.19% of the company’s stock.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.